Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Centessa Pharmaceuticals (Nasdaq: CNTA), a clinical-stage pharmaceutical company, has announced its management team's participation in two upcoming investor conferences in June 2025:
- The Jefferies 2025 Global Healthcare Conference on June 4, with a fireside chat at 11:40 AM ET
- The Goldman Sachs 46th Annual Global Healthcare Conference on June 10, with a fireside chat at 9:20 AM ET
Live webcasts and archived recordings of both events will be accessible through the \"Events and Publications\" section on Centessa's investor relations website.
Details
News Market Reaction – CNTA
The recorded move for CNTA in the trading session of this news was -2.00%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON and LONDON, May 19, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the following investor conferences:
Event: Jefferies 2025 Global Healthcare Conference
Date: June 4, 2025
Fireside Chat: 11:40 AM ET
Event: Goldman Sachs 46th Annual Global Healthcare Conference
Date: June 10, 2025
Fireside Chat: 9:20 AM ET
Access to the live webcasts of these events, as well as archived recordings, will be available under the “Events and Publications” tab on the investor relations section of the Centessa Pharmaceuticals website at https://investors.centessa.com/.
About Centessa Pharmaceuticals
Centessa Pharmaceuticals, plc is a clinical-stage pharmaceutical company with a mission to discover, develop and ultimately deliver medicines that are transformational for patients. We are pioneering a new class of potential therapies within our orexin receptor 2 (OX2R) agonist program for the treatment of excessive daytime sleepiness (EDS), impaired attention, cognitive deficits and fatigue across neurological, neurodegenerative and neuropsychiatric disorders. We also have an early-stage immuno-oncology program focused on our novel LockBody® technology platform. For more information, visit www.centessa.com, which does not form part of this release.
Contact:
Kristen K. Sheppard, Esq.
SVP of Investor Relations
investors@centessa.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.